Surgalign Sees FY21 Sales $95M-$100M vs $107.86M Est.
The Company has revised its outlook for the year and now expects full year revenue in the range of $95 million to $100 million compared to previous
Quidel Stock Falls As Q2 Earnings Miss Street Estimates On Lower COVID-19, Influenza Product Sales
Quidel Corporation (NASDAQ:QDEL) reported after the close of the market Thursday that its second-quarter revenues fell 12% Y/Y to $176.6…
Magna Shares Slide On Q2 Earnings Miss As Chip Shortage Bites; Cuts FY21 Outlook
Magna International Inc (NYSE:MGA) reported second-quarter FY21 sales growth of 110% year-on-year, to $9.03 billion, missing the analyst consensus of $9.37…
Illumina Q2 Earnings Boosted By Robust Growth In Core Sequencing Business; Uplifts FY21 Outlook
Illumina Inc (NASDAQ:ILMN) reported after the close of the market on Thursday that its second-quarter revenues grew 78% Y/Y to…
DraftKings: Q2 Earnings Insights
Shares of DraftKings (NASDAQ:DKNG) rose 2.9% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 38.18% year over year to ($0.76), which missed the estimate of ($0.52).
Broadwind: Q2 Earnings Insights
Shares of Broadwind (NASDAQ:BWEN) moved higher by 6.3% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 1666.67% over the past year to $0.53, which beat the estimate of $0.12.
Recap: Dominion Energy Q2 Earnings
Shares of Dominion Energy (NYSE:D) were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 7.32% year over year to $0.76, which missed the estimate of $0.77.
Recap: NeoGenomics Q2 Earnings
Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share were up 75.00% year over year to ($0.01), which beat the estimate of ($0.06).
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Twist Bioscience Raises FY21 Sales Guidance From Sales $121M-$129M To $129M-$132M vs $127.12M Est.
Updated Fiscal 2021 Financial Guidance
The following statements are based on Twist's current expectations for fiscal 2021. The following statements are forward-looking, and actual results could differ